Table 1.
Summary of studies on FSGS recurrence after kidney transplantation
| Study | Study design | Nation | Number of patients | Age at FSGS diagnosis (years) | Age at transplantation (years) | Time to ESKD (months) | Number of recurrent patients, n (%) | Time to relapse of FSGS (days) |
Treatment | Treatment response (CR/PR) |
|---|---|---|---|---|---|---|---|---|---|---|
| Uffing et al. [11] | Retrospective |
Europe, Brazil, and US |
176 | 27 | 38 | 38 | 57 (32%) | 45 |
PP PP + RTX |
CR/PR: 28%/44% CR/PR: 17%/30% |
| Lanaret et al. [2] | Retrospective | France | 914 | 25.4 | 39.9 | 68 | 165 (18%) | 7 |
SOC + late RTX SOC + early RTX |
CR/PR: 45.9%/36.7% CR/PR: 48.7%/23.1% |
| Kwon et al. [8] | Retrospective | South Korea | 99 | - | 37.1 | 70 | 21 (21%) | 6 | PP ± RTX | CR/PR: 39.1%/47.6% |
| Wood et al. [12] | Retrospective | United States | 100 | - | 34.3 | - | 26 (26%) | 4.5 | PP ± RTX | CR + PR: 72% |
Abbreviations: FSGS, focal segmental glomerulosclerosis; ESKD, end-stage kidney disease; CR, complete remission; PR, partial remission; PP, plasmapheresis; RTX, rituximab; SOC, standard of care